beta-aminoarteether maleate profile

beta-aminoarteether maleate: an immunosuppressive agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

beta-aminoarteether maleate : The maleate salt of beta-aminoarteether. Synthetic artemisinin derivative with potent immunosuppressive activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	86289593
CHEBI ID	78570
MeSH ID	M0547441

Synonym
sm934
CHEBI:78570
10-(beta-aminoethoxy)dihydroartemisinin maleate
beta-aminoarteether maleate
2-[[(3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]ethanamine ethanedioate (1:1)
beta-2'-aminoarteether maleate
2-{[(1r,4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0(4,13).0(8,13)]hexadec-10-yl]oxy}ethanamine ethanedioate (1:1)
2-(10beta-dihydroartemisinoxy)ethylamine maleate
Q27147854

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
" In addition to antimalarial, artemisinin and its derivatives possess distinguished anti-cancer, anti-oxidant, anti-inflammatory and anti-viral activities, but the poor solubility and low bioavailability hinder their clinical application."	( Artemisinin derivative SM934 in the treatment of autoimmune and inflammatory diseases: therapeutic effects and molecular mechanisms. Chen, L; He, SJ; Tong, X; Zuo, JP, 2022)	0.72

Dosage Studied

Excerpt	Relevance	Reference
" In the current study, we further investigated the therapeutic effects of a modified dosage regimen of SM934 on lupus-prone MRL/lpr mice and explored its effects on B cell responses, a central pathogenic event in systemic lupus erythematosus (SLE)."	( Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation. Bai, B; He, P; He, S; Lin, Z; Tang, W; Wu, Y; Xue, L; Yang, X; Zhang, L; Zhu, F; Zuo, J, 2016)	0.43
" The beneficial effects associated with artemisinin treatment include improving symptoms, reducing level of antibodies and proteinuria, ameliorating renal damage, and diminishing the dosage of prednisone use."	( Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review. Mu, X; Wang, C, 2018)	0.48

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
allergen	A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
maleate salt	Salts from maleic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.69)	29.6817
2010's	9 (69.23)	24.3611
2020's	3 (23.08)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (15.38%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (84.62%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	4.87	5	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
artesunic acid [no description available]	3.27	1
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.96	1
scopolamine hydrobromide [no description available]	2.31	1
myelin oligodendrocyte glycoprotein (35-55) [no description available]	2.08	1

Condition	Relationship Strength	Studies
Autoimmune Disease [description not available]	3.33	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.65	5
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	3.33	1
Innate Inflammatory Response [description not available]	2.72	2
Dry Eye [description not available]	2.31	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.72	2
Dry Eye Syndromes Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.	2.31	1
Libman-Sacks Disease [description not available]	3.95	4
Glomerulonephritis, Lupus [description not available]	2.59	2
Anti-Phospholipid Antibody Syndrome [description not available]	2.31	1
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	3.95	4
Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).	2.59	2
Antiphospholipid Syndrome The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).	2.31	1
Colitis Gravis [description not available]	2.17	1
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.17	1
Breast Cancer [description not available]	2.21	1
Metastase [description not available]	2.21	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.21	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.21	1
Allergic Encephalomyelitis [description not available]	2.08	1
Cirrhosis [description not available]	2.11	1
Extramembranous Glomerulopathy [description not available]	2.11	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.11	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.11	1
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2.11	1
Glomerulonephritis, Membranous A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.	2.11	1
Disease Exacerbation [description not available]	2.13	1
Adenopathy [description not available]	2.13	1
Enlarged Spleen [description not available]	2.13	1
Adjuvant Arthritis [description not available]	2.13	1
Rheumatoid Arthritis [description not available]	2.13	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.13	1
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	2.07	1
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	2.07	1

beta-aminoarteether maleate

Description

Cross-References

Synonyms (9)

Research Excerpts

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (1)

Research

Studies (13)

Market Indicators

Research Demand Index: 13.02

Study Types

beta-aminoarteether maleate

Description

Cross-References

Synonyms (9)

Research Excerpts

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (1)

Research

Studies (13)

Market Indicators

Research Demand Index: 13.02

Study Types

Related Drugs (5)

Related Conditions (34)